[Clinical observation of Qiliqiangxin capsule combined with recombinant human brain natriuretic peptide in patients with acute heart failure].

Objective: To observe the clinical effect of Qiliqiangxin capsule combined with recombinant human brain natriuretic peptide in acute left heart failure patients 7 days after onset as well as the effects of plasma MDA and ET-1. Methods: In total, 240 hospitalized patients with acute left heart failure from October 2017 to May 2021 were selected from the Department of Emergency and Critical Care Center of Beijing Anzhen Hospital, Capital Medical University and the Department of Cardiology of the Jilin Provincial People's Hospital. They were randomly divided into routine treatment group and combined treatment group, with 120 cases in each group. The routine treatment group was treated with vasodilation, diuresis, cardiotonic and recombinant human brain natriuretic peptide. The combined treatment group was treated with Qiliqiangxin capsules based on the routine treatment group. One week later, the changes in clinical efficacy, ejection fraction, left ventricular commoid diameter, and plasma BNP, MDA, and ET-1 were compared between the two groups before and after treatment. SPSS 11.5 statistical software was used. The measurement data was expressed in x¯±s, the independent sample t-test was used for comparison between groups, and the paired t-test was used for comparison before and after treatment within groups. Counting data was expressed as case (%), and the rank sum test was used for inter-group comparison. Result: In terms of clinical efficacy, the total effective rate of the combined treatment group was significantly higher than that of the conventional treatment group, and the difference was statistically significant (P<0.05). Compared with the routine treatment group, the left ventricular ejection fraction in the combined treatment group was significantly increased (P<0.05). The levels of plasma BNP, MDA and ET-1 were significantly decreased (P<0.05). Conclusion: Qiliqiangxin capsule combined with rhBNP treatment can effectively improve the clinical symptoms of acute heart failure, as well as reduce the lipid peroxidation product MDA content and endothetin ET-1 level in blood. The clinical application value of the Qiliqiangxin capsule needs to be further confirmed by further trials.目的： 观察芪苈强心胶囊联合重组人脑利钠肽对急性左心衰患者发病后7 d的临床疗效及血浆丙二醛（MDA）和内皮素（ET-1）的影响。 方法： 随机对照研究。选取首都医科大学附属北京安贞医院急诊危重症中心与吉林省人民医院心内科2017年10月至2021年5月因急性左心衰竭入院患者240例，按照随机数字表法分为常规治疗组和联合治疗组，各120例。常规治疗组予以扩血管、利尿、强心、重组人脑利钠肽（BNP）等治疗。联合治疗组在常规治疗组的基础上予以芪苈强心胶囊口服治疗。治疗1周后，比较两组患者治疗前后临床疗效、射血分数、左室舒张末期内径，以及血浆BNP、MDA和ET-1的变化。采用SPSS 11.5统计学软件处理。计量资料以x¯±s表示，组间比较采用独立样本t检验，组内治疗前后比较采用配对t检验。计数资料用例（%）表示，组间比较采用秩和检验。 结果： 从临床疗效看，联合治疗组患者总的有效率明显高于常规治疗组，差异有统计学意义（P<0.05）；联合治疗组患者左室射血分数明显高于常规治疗组（P<0.05）；而联合治疗组血浆BNP、MDA和ET-1含量明显低于常规治疗组（P<0.05）。 结论： 芪苈强心胶囊联合重组人脑利钠肽能有效地改善急性心力衰竭患者治疗后7 d的临床症状，降低血中脂质过氧化产物MDA含量和ET-1水平，在临床的应用价值需要更多的试验进一步证实。.